Site map
An overview of the available content on this site. Keep the pointer still over an item for a few seconds to get its description.
- Volunteers
- How does the study work?
- Funding
- Long-term study
- Downloads
- Contact Us
- Newsletters
-
Privacy Notice: ASCEND
- Who is responsible for your data?
- Personal data we collect about you
- Why we collect and process your data
- How we use your personal data
- How long we keep your data
- How we protect your data
- Sharing your data
- Transfer of your data outside of the European Economic Area (EEA)
- Your rights
- Changes to this policy
- Complaints
- Contact
- Download ASCEND Privacy Notice
-
Privacy Notice: ASCEND-Eye
- What is the purpose of the ASCEND-Eye study?
- How is information collected about me by the ASCEND-Eye study?
- Is the information collected about me secure?
- Sharing your data
- How long is my personal data held by the ASCEND-Eye team?
- Who is responsible for my data?
- What is the lawful basis of the ASCEND-Eye study?
- What are my data rights?
- When will my participation in the study finish?
- What if I want to withdraw from the study?
- Major new study could help protect millions with type 2 diabetes from cardiovascular disease
- ASCEND trial results announced: bleeds and benefit with aspirin balanced in patients with diabetes and no effect on cancer
- ASCEND trial results announced: fish oils do not prevent heart attack or strokes in people with diabetes
- ASCEND-EYE sub-study has been launched
- ASCEND awarded funding from Alzheimer’s Research UK to assess brain power
- New guidelines for the treatment of adults with type 2 diabetes from NICE
- Aspirin no longer recommended to reduce stroke risk in people with atrial fibrillation (AF)
- NEJM animation illustrates ASCEND Aspirin trial results
- Long-term, low-dose aspirin did not affect risk of dementia in adults with type 2 diabetes